Search by drug, manufacturer, or indication

Displaying 211 - 220 of 1165

Yesintek (ustekinumab)

Status:

Concluded with an LOI

Manufacturer:

Biocon Biologics Canada Inc.

Indication:

Multiple Indications

Last updated September 16, 2025

Otulfi (ustekinumab)

Status:

Concluded with an LOI

Manufacturer:

Fresenius Kabi Canada Ltd.

Indication:

Multiple Indications

Last updated September 16, 2025

Opdivo (nivolumab)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

With doxorubicin, vinblastine and dacarbazine (AVD) in previously untreated stage III or IV Hodgkin Lymphoma.

Last updated September 4, 2025

Rystiggo (rozanolixizumab)

Status:

Concluded with an LOI

Manufacturer:

UCB Canada Inc.

Indication:

Generalized myasthenia gravis (gMG)

Last updated August 29, 2025

Idenos (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Apotex Inc.

Indication:

Multiple Indications

Last updated August 29, 2025

Osdenza (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Apotex Inc.

Indication:

Osteoporosis

Last updated August 29, 2025

Zilbrysq (zilucoplan)

Status:

Concluded with an LOI

Manufacturer:

UCB Canada Inc.

Indication:

Generalized myasthenia gravis (gMG)

Last updated August 29, 2025

Bilprevda (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Organon Canada Inc.

Indication:

Multiple Indications

Last updated August 28, 2025

Bildyos (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Organon Canada Inc.

Indication:

Multiple Indications

Last updated August 28, 2025

Ebglyss (lebrikizumab)

Status:

Concluded with an LOI

Manufacturer:

Eli Lilly Canada Inc.

Indication:

Atopic dermatitis

Last updated August 28, 2025